0000899243-21-034546.txt : 20210830 0000899243-21-034546.hdr.sgml : 20210830 20210830203949 ACCESSION NUMBER: 0000899243-21-034546 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210826 FILED AS OF DATE: 20210830 DATE AS OF CHANGE: 20210830 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dalal Anupam CENTRAL INDEX KEY: 0001602474 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38560 FILM NUMBER: 211225187 MAIL ADDRESS: STREET 1: 88 KEARNY STREET, SUITE 1800 CITY: SAN FRANCISCO STATE: CA ZIP: 94108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aadi Bioscience, Inc. CENTRAL INDEX KEY: 0001422142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611547850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 BUSINESS PHONE: 424-473-8055 MAIL ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 FORMER COMPANY: FORMER CONFORMED NAME: Aerpio Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20170316 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP II DATE OF NAME CHANGE: 20071227 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-08-26 0 0001422142 Aadi Bioscience, Inc. AADI 0001602474 Dalal Anupam C/O AADI BIOSCIENCE, INC. 17383 SUNSET BOULEVARD, SUITE A250 ALISO VIEJO CA 92656 1 0 0 0 Common Stock 2021-08-26 4 P 0 1529402 13.077 A 1529402 I See footnote Common Stock 1130 D Stock option (right to buy) 26.00 2021-08-27 4 A 0 17549 0.00 A 2031-08-27 Common Stock 17549 17549 D Consists of (i) 1,284,698 shares held by Acuta Capital Fund, LP ("Acuta Capital") and (ii) 244,704 shares held by Acuta Opportunity Fund, LP. ("Acuta Opportunity Fund"). Acuta Capital Partners, LLC ("Acuta Partners") is the general partner of each of Acuta Capital and Acuta Opportunity Fund. The Reporting Person is the Chief Investment Officer and Manfred Yu is the Manager of Acuta Partners. Both the Reporting Person and Mr. Yu have voting and investment authority over all of the shares held by each of Actua Capital and Acuta Opportunity Fund. Each of Acuta Partners, The Reporting Person and Mr. Yu disclaims beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein. In connection with the closing of the merger by and between Aerpio Pharmaceuticals, Inc. and Aadi Bioscience, Inc., as approved by the stockholders of the Issuer on August 17, 2021, the Board granted on August 26, 2021 to the Reporting Person an Initial Award (as defined in the Issuer's Outside Director Compensation Policy and in accordance with the Issuer's 2021 Equity Incentive Plan (the "Plan")). Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month). The grant date is August 27, 2021. Exhibit 24 - Power of Attorney /s/ Neil Desai, as Attorney-in-Fact 2021-08-30 EX-24 2 attachment1.htm EX-24 DOCUMENT

                               POWER OF ATTORNEY

      The undersigned, as a Section 16 reporting person of Aadi Bioscience, Inc.
(the "Company"), hereby constitutes and appoints Neil Desai, Lance Thibault,
Daniel Koeppen, Kassandra Castillo, Savir Punia and Bridget Balisy the
undersigned's true and lawful attorneys-in-fact to:

      1.    complete and execute Forms 3, 4 and 5 and other forms and all
            amendments thereto as such attorneys-in-fact shall in their
            discretion determine to be required or advisable pursuant to Section
            16 of the Securities Exchange Act of 1934 (as amended) and the rules
            and regulations promulgated thereunder, or any successor laws and
            regulations, as a consequence of the undersigned's ownership,
            acquisition or disposition of securities of the Company; and

      2.    do all acts necessary in order to file such forms with the
            Securities and Exchange Commission, any securities exchange or
            national association, the Company and such other person or agency as
            the attorneys-in-fact shall deem appropriate.

      The undersigned hereby ratifies and confirms all that said attorneys-in-
fact and agent shall do or cause to be done by virtue hereof. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934 (as amended).

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 26th day of August, 2021.


                                        Signature:  /s/ Anupam Dalal
                                                  -------------------------
                                        Print Name:   Anupam Dalal
                                                   ------------------------